September 11, 2012
News Office: Elizabeth Fernandez (415) 502-6397
For two decades, asthma treatment for millions of people with a milder form of the disease has consisted of daily inhaled steroid medicine to reduce inflammation. Now, a new study has found that asthmatics who take the low-dose medication as a daily routine do no better than those who turn to their inhalers only when they have symptoms.
The findings suggest a different, personalized, and far less expensive approach to treating the common inflammatory condition, according to the researchers.
The report will be published in The Journal of the American Medical Association on Sept. 12, 2012.
In effect, the study challenges national and international guidelines that have been in place for 20 years. According to those recommendations, if a person's asthma is mild but persistent, he or she should take an inhaled steroid every day to suppress airway inflammation and reduce the risk of exacerbations.
Mild persistent asthma is one of four types of the disease, which affects as many as one in every 12 people in the United States, according to federal statistics.
"Daily treatment with an inhaled corticosteroid has long been believed to be the best treatment for mild persistent asthma, but it is not followed by the majority of patients," said senior author Dr. Homer A. Boushey, chief of Allergy and Immunology at UCSF Medical Center. A pioneer in the field who has been involved in asthma research for 40 years, Boushey served on the expert committee that developed the current National Institutes of Health's guidelines for managing the disease.
"People don't seem to like taking this type of treatment every day — just a third of the inhaler prescriptions are renewed even once," Boushey said. "So we wondered what would happen if people with mild asthma already well controlled by daily treatment with an inhaled corticosteroid instead took a puff only when they used their rescue medication — usually albuterol — for relief of symptoms."
The upshot: Patients who took inhaled corticosteroid only when they had symptoms wound up using half as much of the medication but did not have more severe symptoms. Nor did they miss more days of work or school, or have more flare-ups.
Called the Best Adjustment Strategy for Asthma in the Longer Term trial (BASALT), the study involved a randomized, double-blinded, placebo-controlled trial conducted by the Asthma Clinical Research Network at 10 academic medical centers across the country including UCSF and the University of Texas Medical Branch.
Altogether, 342 adults with mild to moderate, persistent asthma took part in the study over nine months between 2007 and 2010. All were diagnosed by doctors and all had either reversible airflow limitation or airway hyperresponsiveness. In each case, the participant's asthma was under control due to low-dose inhaled corticosteroids.
The scientists in the study evaluated three different approaches to the use of inhaled corticosteroids:
The researchers found that the frequency of flare-ups or exacerbations of asthma, symptom severity and pulmonary function did not differ among the treatment groups. There was, however, a significant association between the effectiveness of self-administered medicine and race: Hispanic participants did not do as well with day-to-day adjusted treatment. The researchers conjectured that this could reflect linguistic or other social or cultural differences.
"The goal of our study was to compare different approaches to adjusting inhaled corticosteroid treatment on the frequency and severity of asthma attacks and on quality of life," Boushey said. "This is not a treatment breakthrough but it may possibly open the door to a new approach to treatment, and it will certainly be considered by the expert panel for the NIH's guidelines for asthma treatment.
"This approach allows personalization of treatment and is easy for patients. Also, it could hypothetically result in saving $2 billion a year in medication costs," Boushey said.
UCSF co-authors are Dr. John V. Fahy and Dr. Stephen C. Lazarus, both pulmonologists at UCSF Medical Center. The lead authors are Dr. William J. Calhoun and Bill T. Ameredes, of the University of Texas Medical Branch.
"This is a step forward in asthma management," Calhoun said. "It enables patients to use their steroids only when they have symptoms. It is 'temporal personalization,' adjusting medication on a day to day basis."
Asthma has been on the upswing for much of the last century, and is now one of the most common diseases in the world, affecting approximately 300 million people globally including an estimated 24 million people in the U.S., according to the federal Centers for Disease Control and Infection.
More prevalent in western, developed countries, the condition varies in its severity — some people are affected daily, others seasonally or episodically. Asthma is classified into four types based on severity: intermittent, mild persistent, moderate persistent and severe persistent.
The research was supported through funding from the National Heart Lung and Blood Institute, of the National Institutes of Health. Teva Pharmaceuticals provided the study drug and match placebo, but had no input into the experimental design, analysis or manuscript preparation. Both Fahy and Boushey report consultancy work or research support from several companies, including Amgen, Genentech, GSK, Merck and Johnson & Johnson, among others. Full disclosures and grant numbers can be found in the paper.
About UCSF Medical Center
UCSF Medical Center consistently ranks as one of the top 10 hospitals in the United States. Recognized for innovative treatments, advanced technology, collaboration among health care professionals and scientists, and a highly compassionate patient care team, UCSF Medical Center serves as the academic medical center of the University of California, San Francisco. The medical center's nationally preeminent programs include children's health, the brain and nervous system, organ transplantation, women's health and cancer. It operates as a self-supporting enterprise within UCSF and generates its own revenues to cover the operating costs of providing patient care.
This news release has been modified for the website